CULLINAN

Serial Number 97778211
Registration 7797946
700

Registration Progress

Application Filed
Feb 2, 2023
Under Examination
Approved for Publication
Apr 1, 2025
Published for Opposition
Apr 1, 2025
Registered
May 20, 2025

Trademark Image

CULLINAN

Basic Information

Serial Number
97778211
Registration Number
7797946
Filing Date
February 2, 2023
Registration Date
May 20, 2025
Published for Opposition
April 1, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
May 20, 2025
Registration
Registered
Classes
005 042

Rights Holder

CULLINAN THERAPEUTICS, INC.

03
Address
ONE MAIN STREET, SUITE 1350
CAMBRIDGE, MA 02142

Ownership History

Cullinan Oncology, Inc.

Original Applicant
03
Cambridge, MA

CULLINAN THERAPEUTICS, INC.

New Owner Before Publication #1
03
CAMBRIDGE, MA

CULLINAN THERAPEUTICS, INC.

Owner at Publication
03
CAMBRIDGE, MA

CULLINAN THERAPEUTICS, INC.

Original Registrant
03
CAMBRIDGE, MA

Legal Representation

Attorney
Malaika D. Tyson

USPTO Deadlines

Next Deadline
1935 days remaining
Section 8 Declaration Due (Principal Register)
Due Date
May 20, 2031
Grace Period Ends
November 20, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

38 events
Date Code Type Description Documents
Dec 10, 2025 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Dec 10, 2025 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Dec 10, 2025 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
May 20, 2025 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
May 20, 2025 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Apr 1, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Apr 1, 2025 PUBO A PUBLISHED FOR OPPOSITION Loading...
Mar 26, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Mar 10, 2025 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Mar 10, 2025 IUAA P USE AMENDMENT ACCEPTED Loading...
Mar 6, 2025 AUPC I AMENDMENT TO USE PROCESSING COMPLETE Loading...
Mar 6, 2025 IUAF S USE AMENDMENT FILED Loading...
Mar 6, 2025 EAAU I TEAS AMENDMENT OF USE RECEIVED Loading...
Mar 6, 2025 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Mar 6, 2025 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Mar 6, 2025 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Dec 12, 2024 XELG O APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Loading...
Dec 12, 2024 XELR I APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Loading...
Sep 25, 2024 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Loading...
Sep 20, 2024 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Sep 20, 2024 GNRT F NON-FINAL ACTION E-MAILED Loading...
Sep 20, 2024 CNRT R NON-FINAL ACTION WRITTEN Loading...
Sep 5, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Sep 5, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Sep 5, 2024 ERFR I TEAS REQUEST FOR RECONSIDERATION RECEIVED Loading...
Jun 5, 2024 XELG O APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Loading...
Jun 5, 2024 XELR I APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Loading...
Mar 7, 2024 GNFN O NOTIFICATION OF FINAL REFUSAL EMAILED Loading...
Mar 7, 2024 GNFR O FINAL REFUSAL E-MAILED Loading...
Mar 7, 2024 CNFR R FINAL REFUSAL WRITTEN Loading...
Feb 8, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Feb 7, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Feb 7, 2024 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Nov 7, 2023 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Nov 7, 2023 GNRT F NON-FINAL ACTION E-MAILED Loading...
Nov 7, 2023 CNRT R NON-FINAL ACTION WRITTEN Loading...
Oct 31, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
Feb 21, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical products for the prevention and treatment of cancer; therapeutic pharmaceuticals for the treatment of cancer; anti-cancer preparations being anti-cancer medicines comprised of small molecules and biologics; pharmaceuticals and therapeutic pharmaceuticals for the treatment of cancer and for use in the fields of oncology and immunology
First Use Anywhere: 20191000
First Use in Commerce: 20191000
Class 042
Pharmaceutical research and development; scientific research and development; medical research and development; medical research and development services in the fields of drug discovery and oncology
First Use Anywhere: Feb 4, 2019
First Use in Commerce: Feb 4, 2019

Classification

International Classes
005 042